Neurosense Therapeutics Net Worth
Neurosense Therapeutics Net Worth Breakdown | NRSN |
Neurosense Therapeutics Net Worth Analysis
Neurosense Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Neurosense Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Neurosense Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Neurosense Therapeutics' net worth analysis. One common approach is to calculate Neurosense Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Neurosense Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Neurosense Therapeutics' net worth. This approach calculates the present value of Neurosense Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Neurosense Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Neurosense Therapeutics' net worth. This involves comparing Neurosense Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Neurosense Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Neurosense Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neurosense Therapeutics' net worth research are outlined below:
| Neurosense Therapeutics generated a negative expected return over the last 90 days | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Neurosense Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Neurosense Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Financial Analysis Emmaus Life Sciences versus NeuroSense Therapeutics |
Neurosense Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neurosense Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neurosense Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Neurosense Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neurosense Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neurosense Therapeutics backward and forwards among themselves. Neurosense Therapeutics' institutional investor refers to the entity that pools money to purchase Neurosense Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Xtx Topco Ltd | 2024-09-30 | 46 K | Woodline Partners Lp | 2024-06-30 | 0.0 | Meitav Dash Investments Ltd | 2024-09-30 | 40 K | Citadel Advisors Llc | 2024-09-30 | 34.3 K | Commonwealth Equity Services Inc | 2024-09-30 | 12.6 K | Geode Capital Management, Llc | 2024-09-30 | 12 K | Cwm, Llc Duplicate | 2024-09-30 | 1000 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 |
Follow Neurosense Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.89 M.Market Cap |
|
Project Neurosense Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.18) | (3.34) | |
| Return On Capital Employed | 42.58 | 44.70 | |
| Return On Assets | (3.18) | (3.34) | |
| Return On Equity | 5.39 | 5.66 |
When accessing Neurosense Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Neurosense Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neurosense Therapeutics' profitability and make more informed investment decisions.
Evaluate Neurosense Therapeutics' management efficiency
Neurosense Therapeutics has return on total asset (ROA) of (1.5079) % which means that it has lost $1.5079 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9484) %, meaning that it created substantial loss on money invested by shareholders. Neurosense Therapeutics' management efficiency ratios could be used to measure how well Neurosense Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Neurosense Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 15th of December 2024, Return On Equity is likely to grow to 5.66, while Return On Tangible Assets are likely to drop (3.34). At this time, Neurosense Therapeutics' Total Assets are very stable compared to the past year. As of the 15th of December 2024, Net Tangible Assets is likely to grow to about 10.9 M, while Non Current Assets Total are likely to drop about 154 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.14) | (0.13) | |
| Tangible Book Value Per Share | (0.14) | (0.13) | |
| Enterprise Value Over EBITDA | (0.77) | (0.81) | |
| Price Book Value Ratio | (5.71) | (5.43) | |
| Enterprise Value Multiple | (0.77) | (0.81) | |
| Price Fair Value | (5.71) | (5.43) | |
| Enterprise Value | 12.3 M | 12.9 M |
Leadership at Neurosense Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Return On Equity (4.95) |
Neurosense Therapeutics Earnings per Share Projection vs Actual
Neurosense Therapeutics Corporate Management
| Sharon Vered | Global CMC | Profile | |
| Diana Shtossel | Head Affairs | Profile | |
| Or Eisenberg | Chief Officer | Profile | |
| Nedira SalzmanFrenkel | Global Devel | Profile | |
| Yael Barak | Head Compliance | Profile | |
| Alon BenNoon | CEO CoFounder | Profile | |
| Hagit Binder | VP Operations | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.